JP2023549322A5 - - Google Patents

Info

Publication number
JP2023549322A5
JP2023549322A5 JP2023525997A JP2023525997A JP2023549322A5 JP 2023549322 A5 JP2023549322 A5 JP 2023549322A5 JP 2023525997 A JP2023525997 A JP 2023525997A JP 2023525997 A JP2023525997 A JP 2023525997A JP 2023549322 A5 JP2023549322 A5 JP 2023549322A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
amino acid
region
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549322A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2021/016629 external-priority patent/WO2022103220A1/ko
Publication of JP2023549322A publication Critical patent/JP2023549322A/ja
Publication of JP2023549322A5 publication Critical patent/JP2023549322A5/ja
Pending legal-status Critical Current

Links

JP2023525997A 2020-11-13 2021-11-15 治療学的酵素融合タンパク質のファブリー病に起因する又は伴うニューロパチーの予防及び治療用途 Pending JP2023549322A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200152246 2020-11-13
KR10-2020-0152246 2020-11-13
PCT/KR2021/016629 WO2022103220A1 (ko) 2020-11-13 2021-11-15 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신경병증 예방 및 치료 용도

Publications (2)

Publication Number Publication Date
JP2023549322A JP2023549322A (ja) 2023-11-24
JP2023549322A5 true JP2023549322A5 (cg-RX-API-DMAC7.html) 2024-11-25

Family

ID=81601490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525997A Pending JP2023549322A (ja) 2020-11-13 2021-11-15 治療学的酵素融合タンパク質のファブリー病に起因する又は伴うニューロパチーの予防及び治療用途

Country Status (12)

Country Link
US (1) US20230416714A1 (cg-RX-API-DMAC7.html)
EP (1) EP4245310A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023549322A (cg-RX-API-DMAC7.html)
KR (1) KR20220065720A (cg-RX-API-DMAC7.html)
CN (1) CN116419759A (cg-RX-API-DMAC7.html)
AU (1) AU2021377712A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196264A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006516A2 (cg-RX-API-DMAC7.html)
IL (1) IL302857A (cg-RX-API-DMAC7.html)
MX (1) MX2023005579A (cg-RX-API-DMAC7.html)
WO (1) WO2022103220A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304536B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230134823A (ko) * 2022-03-15 2023-09-22 주식회사 녹십자 α-갈락토시다제 A의 융합단백질을 포함하는 동결 건조 제제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO2015009052A1 (ko) * 2013-07-16 2015-01-22 일동제약 주식회사 하이브리드 면역글로불린 fc와 효소의 융합단백질
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
US12194079B2 (en) * 2017-01-05 2025-01-14 Protalix Ltd. Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase
US11357834B2 (en) * 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
US20200157172A1 (en) * 2017-07-07 2020-05-21 HANMl PHARM. CO., LTD. Novel therapeutic enzyme fusion protein and use thereof
EP3708661A4 (en) * 2017-12-22 2021-12-01 Hanmi Pharm. Co., Ltd. THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE

Similar Documents

Publication Publication Date Title
US12522641B2 (en) Targeted mutant interferon-gamma and uses thereof
JP2019137675A5 (cg-RX-API-DMAC7.html)
US12583898B2 (en) Therapeutic interferon alpha 1 proteins
US20220096596A1 (en) Method of treating amd in patients refractory to anti-vegf therapy
JP2021007390A5 (cg-RX-API-DMAC7.html)
JP2021533779A5 (cg-RX-API-DMAC7.html)
JP2023181445A5 (cg-RX-API-DMAC7.html)
JP2020508068A5 (cg-RX-API-DMAC7.html)
JP2022526799A (ja) イズロン酸2-スルファターゼを含むタンパク質分子の製剤
JP2022526799A5 (cg-RX-API-DMAC7.html)
JP2021512899A5 (cg-RX-API-DMAC7.html)
WO2018028635A1 (zh) 一种寨卡病毒人源单克隆抗体及其应用
US20220194993A1 (en) Flagellin fusion protein and use thereof
JP2006514607A5 (cg-RX-API-DMAC7.html)
KR20150023957A (ko) 혈소판-유래 성장인자에 결합하는 설계된 안키린 반복 단백질
JP2020503262A5 (ja) アクチビンIIa型受容体変異体および同変異体を含む医薬組成物
JP2020528743A5 (cg-RX-API-DMAC7.html)
JPH07504808A (ja) Cdrをグラフトしたヒト化キメラt細胞抗体
CN107106651A (zh) 用于治疗眼病的肽和包含所述肽的用于治疗眼病的组合物
US20140113853A1 (en) Transducible Polypeptides for Modifying Metabolism
JP2023544211A5 (cg-RX-API-DMAC7.html)
JP2023545707A5 (cg-RX-API-DMAC7.html)
JP2024504777A5 (cg-RX-API-DMAC7.html)
EP4323392A1 (en) Il-2 based constructs
JP2023554379A5 (cg-RX-API-DMAC7.html)